This article is more than 1 year old.

Biocon, Mylan's diabetic drug receives positive opinion from European Medicines Agency committee

Mini

Biotechnology firm Biocon on Monday said its subsidiary Biocon Biologics and Mylan have received a positive opinion from the European Medicines Agency's committee for medicinal products for human use (CHMP) recommending approval of the market authorisation of their product 'Kixelle' use for the treatment of type 1 and 2 diabetes. "Biocon Biologics and Mylan (a subsidiary of Viatris Inc.) have received a positive opinion from the European Medicines Agency's committee for medicinal products for human use (CHMP) recommending approval of the market authorisation of Kixelle, a biosimilar Insulin Aspart, which is a rapid acting insulin for the treatment of type 1 and 2 diabetes," Biocon said in a regulatory filing. Biocon said the CHMP positive opinion will be considered by the European Commission. The European Commission decision on the approval is expected early next year. Christiane Hamacher, CEO, Biocon Biologics, said the company will look forward to a final decision from the European Commission approving Insulin Aspart "which will enable us to expand our offering to people with diabetes to include a rapid acting insulin analog along with a long acting insulin glargine". Shares of Biocon were trading 0.58 per cent lower at Rs 452.25 apiece on BSE.

Biocon, Mylan's diabetic drug receives positive opinion from European Medicines Agency committee
Biotechnology firm Biocon on Monday said its subsidiary Biocon Biologics and Mylan have received a positive opinion from the European Medicines Agency’s committee for medicinal products for human use (CHMP) recommending approval of the market authorisation of their product ’Kixelle’ use for the treatment of type 1 and 2 diabetes.
”Biocon Biologics and Mylan (a subsidiary of Viatris Inc.) have received a positive opinion from the European Medicines Agency’s committee for medicinal products for human use (CHMP) recommending approval of the market authorisation of Kixelle, a biosimilar Insulin Aspart, which is a rapid acting insulin for the treatment of type 1 and 2 diabetes,” Biocon said in a regulatory filing.
Also Read
Biocon said the CHMP positive opinion will be considered by the European Commission. The European Commission decision on the approval is expected early next year. Christiane Hamacher, CEO, Biocon Biologics, said the company will look forward to a final decision from the European Commission approving Insulin Aspart ”which will enable us to expand our offering to people with diabetes to include a rapid-acting insulin analog along with a long-acting insulin glargine”. Shares of Biocon were trading 0.58 percent lower at Rs 452.25 apiece on BSE.
next story

Market Movers

Currency

CompanyPriceChng%Chng